Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab vs Pembrolizumab in Advanced NSCLC (CTONG1901)
NCT04252365Phase 2Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Status: unknown.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04252365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252365.